TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
CEO Ugur Sahin highlighted that BioNTech maintained its leadership in the COVID vaccine market, launching a variant-adapted vaccine in partnership with Pfizer, now distributed in over 180 countries ...
Bristol-Myers Squibb Co. BMY on Tuesday announced a partnership with Hengrui Pharma to develop a portfolio of 13 early-stage programs spanning oncology, hematology and immunology. The deal follows the ...
SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results